## COPY FROM PARENT



## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

ATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)			
on 6 :		(11) International Publication Number:	WO 98/11435
1/32, A61K	A1	(43) International Publication Date:	19 March 1998 (19.03.98)
er: PCT/GB  I September 1997 (  mber 1996 (11.09.9)  Fales except US): B/GB]; Bouverie Ho	11.09.9 6) G HOEF	BY, CA, CH, CN, CU, CZ, DE GH, HU, ID, IL, IS, JP, KE, K LR, LS, LT, LU, LV, MD, MG, NZ, PL, PT, RO, RU, SD, SE, SI TT, UA, UG, US, UZ, VN, YU KE, LS, MW, SD, SZ, UG, ZW) BY, KG, KZ, MD, RU, TJ, TM), CH, DE, DK, ES, FI, FR, GB, PT, SE), OAPI patent (BF, BJ, C	, DK, EE, ES, FI, GB, GE, GC, KP, KR, KZ, LC, LK, MK, MN, MW, MX, NO, G, SI, SK, SL, TJ, TM, TR, ZW, ARIPO patent (GH, Eurasian patent (AM, AZ, European patent (AT, BE, GR, IE, IT, LU, MC, NI.
only): RADEMACHER, Foxcombe, The Ridgeway, (GB). MCLEAN, Patricia ars Lane, Richmond, Surrey		Before the expiration of the tin	ne limit for amending the the event of the receipt of
Mewbum Ellis, Yorl HP (GB).	k House		

ODS RELATING TO THE DIAGNOSIS AND TREATMENT OF DIABETES AND OBESITY

the level or ratio of P- and A-type inositolphosphoglycans (IPGs) in a sample from a patient, and antagonists in the treatment of diabetes is disclosed. In particular, the present invention provides tes (NIDDM) with a mixture of P- and A-type mediators, and treatment of obese type II diabetes an A-type antagonist.